Top
Main
 
All Outcomes
 
RCT vs. Obs.
 
Feedback
Home
c19early.org COVID-19 treatment researchSodium BicarbonateSodium Bicar.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Sodium Bicarbonate for COVID-19: real-time meta analysis of 7 studies

@CovidAnalysis, November 2024, Version 1V1
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Baxter (RCT) 65% 0.35 [0.01-8.27] hosp. 0/37 1/42 OT​1 Improvement, RR [CI] Treatment Control Mody (RCT) 64% 0.36 [0.19-0.68] no improv. 8/30 22/30 Soares (ICU) 76% 0.24 [0.11-0.54] death 6/44 18/32 ICU patients Delić (RCT) 23% 0.77 [0.56-1.06] death 23/42 37/52 Intubated patients Delić (RCT) 20% 0.80 [0.54-1.18] death 20/42 31/52 Intubated patients El-Badrawy 57% 0.43 [0.09-2.08] death 3/127 3/55 El-Badrawy 39% 0.61 [0.20-1.83] progression 7/127 5/55 El-Badrawy 19% 0.81 [0.68-0.96] no recov. 84/127 45/55 El-Badrawy 73% 0.27 [0.14-0.52] no recov. 127 (n) 55 (n) El-Badrawy 66% 0.34 [0.25-0.47] recov. time 127 (n) 55 (n) El-Badrawy (RCT) 23% 0.77 [0.50-1.18] death 32/272 42/274 El-Badrawy (RCT) 55% 0.45 [0.23-0.87] death 12/247 27/251 El-Badrawy (RCT) 79% 0.21 [0.02-1.76] death 1/125 5/130 El-Badrawy (RCT) 53% 0.47 [0.25-0.88] death 11/63 22/59 El-Badrawy (RCT) -23% 1.23 [0.86-1.75] death 20/25 15/23 El-Badrawy (RCT) 28% 0.72 [0.66-0.80] recov. time 272 (n) 274 (n) El-Badrawy (RCT) 33% 0.67 [0.52-0.85] no recov. 238 (n) 229 (n) Wang (RCT) 39% 0.61 [0.46-0.82] hosp. time 23 (n) 32 (n) Sodium bicarbonate COVID-19 outcomes c19early.org November 2024 1 OT: comparison with other treatment Favors sodium bicarbonate Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit